Department of Pharmacology

Faculty

< Return to faculty list.

Corey Hopkins, Ph.D.

Research Assistant Professor of Pharmacology
BRET Profile (opens in a new window)
corey.r.hopkins@Vanderbilt.Edu
66892
MRB12478A
Nashville, TN 37232-0697

Education

PhD, University of Pittsburgh
BS, Indiana University

Research Keywords

Medicinal chemistry, Parkinson's disease, GPCR, allosteric modulation, muscarinic receptors, Alzheimer's disease, Schizophrenia, drug discovery

Research Description

Dr. Corey Hopkins is an experienced and highly trained medicinal chemist who has extensive experience in all aspects of medicinal chemistry (hit-to-lead, lead identification, lead optimization, SAR, ADME, pre-IND studies). Dr. Hopkins has been involved in small molecule drug discovery in both industry and academia for more than a decade. During his graduate work, he worked on the total synthesis of complex natural products, synthetic methodology development, and pharmacophore profiling for Cdc25 phosphatase inhibitors. As a medicinal chemist with Sanofi Pharmaceuticals he was a key contributor on a number of projects within the CNS, skeletal and inflammatory related therapeutic targets, such as multiple sclerosis, depression, rheumatoid arthritis and osteoporosis; culminating in several projects advancing into development status. Dr. Hopkins is currently the Associate Director of Medicinal Chemistry for the Vanderbilt Center for Neuroscience Drug Discovery, the Co-Director, Vanderbilt Specialized Chemistry Center for Accelerate Probe Development and an Assistant Professor of Pharmacology and Chemistry. He is currently the chemistry team leader for the development of novel mGlu4 positive allosteric modulators for the treatment of Parkinsona??s disease through a grant from the Michael J. Fox Foundation. In this capacity, Dr. Hopkins is responsible for all aspects of the chemistry effort (design of novel scaffolds, coordination in vitro/in vivo pharmacokinetic studies, in vivo biology studies). This program has now advanced to pre-IND studies for clinical candidate advancement with several compounds exhibiting significant effects in pre-clinical rodent models of PD along with promising pre-clinical toxicology studies.

In addition to his efforts with the mGlu4 project, Dr. Hopkins oversees a team of chemists working on the development of novel M1 positive allosteric modulators for the potential treatment of the cognitive deficits in Alzheimera??s and schizophrenia. Lastly, Dr. Hopkins has had a long standing collaboration with Dr. Charles Hong (Vanderbilt) looking for inhibitors of the BMP pathway for the potential treatment of the rare disease Fibrodysplasia Ossificans Progressiva (FOP) which is a devastating disease in children.

Dr. Hopkins has been the author or co-author on more than 30 original research manuscripts and more than 15 patents along with numerous review articles, book chapters and invited research talks.

Publications

Melancon, BJ, Hopkins, CR, Wood, MR, Emmitte, KA, Niswender, CM, Christopoulos, A, Conn, PJ, Lindsley, CW. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem, 55(4), 1445-64, 2012

Jones, CK, Bubser, M, Thompson, AD, Dickerson, JW, Turle-Lorenzo, N, Amalric, M, Blobaum, AL, Bridges, TM, Morrison, RD, Jadhav, S, Engers, DW, Italiano, K, Bode, J, Daniels, JS, Lindsley, CW, Hopkins, CR, Conn, PJ, Niswender, CM. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson''s disease. J Pharmacol Exp Ther, 340(2), 404-21, 2012

Mueller, R, Dawson, ES, Niswender, CM, Butkiewicz, M, Hopkins, CR, Weaver, CD, Lindsley, CW, Conn, PJ, Meiler, J. Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. J Mol Model, 2012

Salovich, JM, Vinson, PN, Sheffler, DJ, Lamsal, A, Utley, TJ, Blobaum, AL, Bridges, TM, Le, U, Jones, CK, Wood, MR, Scott Daniels, J, Jeffrey Conn, P, Niswender, CM, Lindsley, CW, Hopkins, CR. Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M(4)) receptor. Bioorg Med Chem Lett, 2012

Lindsley, CW, Hopkins, CR. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson''s disease: historical perspective and review of the patent literature. Expert Opin Ther Pat, 22(5), 461-81, 2012

Utley, T, Haddenham, D, Salovich, JM, Zamorano, R, Vinson, PN, Lindsley, CW, Hopkins, CR, Niswender, CM. Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected ''molecular switch'' from a closely related mGlu4 positive allosteric modulator. Bioorg Med Chem Lett, 21(23), 6955-9, 2011

Raphemot, R, Lonergan, DF, Nguyen, TT, Utley, T, Lewis, LM, Kadakia, R, Weaver, CD, Gogliotti, R, Hopkins, C, Lindsley, CW, Denton, JS. Discovery, characterization, and structure-activity relationships of an inhibitor of inward rectifier potassium (Kir) channels with preference for Kir2.3, Kir3.x, and Kir7.1. Front Pharmacol, 2, 75, 2011

Xiang, Z, Thompson, AD, Brogan, JT, Schulte, ML, Melancon, BJ, Mi, D, Lewis, LM, Zou, B, Yang, L, Morrison, R, Santomango, T, Byers, F, Brewer, K, Aldrich, JS, Yu, H, Dawson, ES, Li, M, McManus, O, Jones, CK, Daniels, JS, Hopkins, CR, Xie, XS, Conn, PJ, Weaver, CD, Lindsley, CW. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson''s Disease. ACS Chem Neurosci, 2(12), 730-742, 2011

Hopkins, CR. ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another I?-Secretase Inhibitor Fails in the Clinic. ACS Chem Neurosci, 2(6), 279-80, 2011

Jones, CK, Engers, DW, Thompson, AD, Field, JR, Blobaum, AL, Lindsley, SR, Zhou, Y, Gogliotti, RD, Jadhav, S, Zamorano, R, Bogenpohl, J, Smith, Y, Morrison, R, Daniels, JS, Weaver, CD, Conn, PJ, Lindsley, CW, Niswender, CM, Hopkins, CR. Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J Med Chem, 54(21), 7639-47, 2011

Engers, DW, Field, JR, Le, U, Zhou, Y, Bolinger, JD, Zamorano, R, Blobaum, AL, Jones, CK, Jadhav, S, Weaver, CD, Conn, PJ, Lindsley, CW, Niswender, CM, Hopkins, CR. Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats. J Med Chem, 54(4), 1106-10, 2011

Hopkins, CR. ACS Chemical Neuroscience Molecule Spotlight on Latuda (Lurasidone; SM-13,496). ACS Chem Neurosci, 2(2), 58-9, 2011

Cheung, YY, Zamorano, R, Blobaum, AL, Weaver, CD, Conn, PJ, Lindsley, CW, Niswender, CM, Hopkins, CR. Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlua??. ACS Comb Sci, 13(2), 159-65, 2011

Cross, EE, Thomason, RT, Martinez, M, Hopkins, CR, Hong, CC, Bader, DM. Application of small organic molecules reveals cooperative TGFI? and BMP regulation of mesothelial cell behaviors. ACS Chem Biol, 6(9), 952-61, 2011

Hopkins, CR. ACS Chemical Neuroscience Molecule Spotlight on Gilenya (Fingolimod; FTY720). ACS Chem Neurosci, 2(3), 116-7, 2011

Wood, MR, Hopkins, CR, Brogan, JT, Conn, PJ, Lindsley, CW. &quot;Molecular switches&quot; on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry, 50(13), 2403-10, 2011

Hopkins, CR. ACS Chemical Neuroscience Molecule Spotlight on Saredutant. ACS Chem Neurosci, 1(10), 653-4, 2010

Hopkins, CR. ACS Chemical Neuroscience Molecule Spotlight on Lorcaserin. ACS Chem Neurosci, 1(11), 718-9, 2010

Hopkins, CR. ACS Chemical Neuroscience Molecule Spotlight on Valdoxen. ACS Chem Neurosci, 1(12), 772-3, 2010

Hopkins, CR. ACS Chemical Neuroscience Molecule Spotlight on Dimebon. ACS Chem Neurosci, 1(9), 587-8, 2010